برجاء الإنتظار ...

Search Results



نشرة الممارس الصحي نشرة معلومات المريض بالعربية نشرة معلومات المريض بالانجليزية صور الدواء بيانات الدواء
  SFDA PIL (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)

REYATAZ is a prescription HIV-1 (Human Immunodeficiency Virus-type 1) medicine that is used with other antiretroviral medicines to treat HIV-1 infection in adults. HIV-1 is the virus that causes AIDS (Acquired Immunodeficiency Syndrome).

REYATAZ should not be used in children younger than 3 months of age.

When used with other antiretroviral medicines to treat HIV-1 infection, REYATAZ may help:

·         reduce the amount of HIV-1 in your blood. This is called “viral load”.

·         increase the number of CD4+ (T) cells in your blood that help fight off other infections.

Reducing the amount of HIV-1 and increasing the CD4+ (T) cells in your blood may help improve your immune system. This may reduce your risk of death or getting infections that can happen when your immune system is weak (opportunistic infections).

REYATAZ does not cure HIV-1 infection or AIDS. You must keep taking HIV-1 medicines to control HIV-1 infection and decrease HIV-related illnesses.


a. Do not take REYATAZ if you

·         are allergic to atazanavir or any of the ingredients in REYATAZ. See the end of this leaflet for a complete list of ingredients in REYATAZ.

·         are taking any of the following medicines. Taking REYATAZ with these medicines may affect how REYATAZ works. REYATAZ may cause serious life-threatening side effects or death when used with these medicines:

·         alfuzosin (UROXATRAL®)

·         cisapride (PROPULSID®)

·         elbasvir/grazoprevir (ZEPATIER®)

·         ergot medicines including:

·         ergotamine tartrate (CAFERGOT®, MIGERGOT®, ERGOMAR®, ERGOSTAT®, MEDIHALER®, Ergotamine, WIGRAINE®, WIGRETTES®)

·         dihydroergotamine mesylate (D.H.E. 45®, MIGRANAL®)

·         methylergonovine (METHERGINE®)

·         glecaprevir/pibrentasvir (MAVYRET®)

·         indinavir (CRIXIVAN®)

·         irinotecan (CAMPTOSAR®)

·         lurasidone (LATUDA®) if REYATAZ is used with ritonavir (NORVIR®)

·         lovastatin (ADVICOR®, ALTOPREV®, MEVACOR®)

·         midazolam (VERSED®), when taken by mouth for sedation

·         nevirapine (VIRAMUNE®, VIRAMUNE XR®)

·         pimozide (ORAP®)

·         rifampin (RIFADIN®, RIFAMATE®, RIFATER®, RIMACTANE®)

·         sildenafil (REVATIO®), when used for the treatment of pulmonary arterial hypertension

·         simvastatin (SIMCOR®, VYTORIN®, ZOCOR®)

·         St. John’s wort (Hypericum perforatum)

·         triazolam (HALCION®)

Serious problems can happen if you or your child takes any of the medicines listed above with REYATAZ.

b. Take special care with REYATAZ

What should I tell my healthcare provider before taking REYATAZ?

Before taking REYATAZ, tell your healthcare provider if you:

·         have heart problems

·         have liver problems, including hepatitis B or C virus infection

·         are receiving dialysis treatment

·         have diabetes

·         have hemophilia

·         have any other medical conditions

c. Taking other medicines, herbal or dietary supplements

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Some medicines interact with REYATAZ. Keep a list of your medicines to show your healthcare provider and pharmacist. You can ask your healthcare provider or pharmacist for a list of medicines that interact with REYATAZ. Do not start taking a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take REYATAZ with other medicines.

 

 

d. Taking REYATAZ with food and drink

See How to take REYATAZ (4).

 

e. Pregnancy and breast-feeding

Before taking REYATAZ, tell your healthcare provider if you:

·         Are pregnant or plan to become pregnant. Talk to your healthcare provider about taking REYATAZ during your pregnancy or if you are planning to become pregnant while you are taking REYATAZ.

·         Hormonal forms of birth control, such as injections, vaginal rings, or implants, contraceptive patch, and some birth control pills may not work during treatment with REYATAZ. Talk to your healthcare provider about forms of birth control that may be used during treatment with REYATAZ.

·         After your baby is born, tell your healthcare provider if your baby’s skin or the white part of the eyes turns yellow.

·         Are breastfeeding or plan to breastfeed. Do not breastfeed if you are taking REYATAZ. You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby. REYATAZ can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby.

f. Driving and using machines

Patients should be informed that dizziness has been reported during treatment with regimens containing REYATAZ.

g. Important information about some of the ingredients of REYATAZ

REYATAZ contains lactose. If you have been told by your doctor that you have an intolerance to some sugars (e.g., lactose), talk to your doctor before taking REYATAZ


·         Take REYATAZ exactly as your healthcare provider tells you to.

·         Do not change your dose or stop taking REYATAZ unless your healthcare provider tells you to.

·         Stay under the care of your healthcare provider during treatment with REYATAZ.

·         REYATAZ must be used with other antiretroviral medicines

·         Take REYATAZ 1 time each day.

·         REYATAZ comes as capsules.

·         Take REYATAZ capsules with food.

·         Swallow the capsules whole. Do not open the capsules.

·         If you miss a dose of REYATAZ, take it as soon as you remember. Then take the next dose at your regular time. Do not take 2 doses at the same time.

·         If you take too much REYATAZ, call your healthcare provider or go to the nearest hospital emergency room right away.

When your supply of REYATAZ starts to run low, get more from your healthcare provider or pharmacy. It is important not to run out of REYATAZ. The amount of HIV-1 in your blood may increase if the medicine is stopped for even a short time. The virus may become resistant to REYATAZ and harder to treat.


Like all medicines, REYATAZ can cause side effects, although not everybody gets them.

The most common side effects of REYATAZ include:

·         Nausea

·         Headache

·         Stomach-area pain

·         Vomiting

·         Trouble sleeping

·         Numbness, tingling, or burning of hands or feet

·         Dizziness

·         Muscle pain

·         Diarrhea

·         Depression

·         Fever

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of REYATAZ. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects.


·         Store REYATAZ capsules at room temperature, between 20°C to 25°C.

·         Keep capsules in a tightly closed container.

Keep REYATAZ and all medicines out of the reach of children.

 


·         Active Ingredient: atazanavir sulfate (in 150 mg and 200 mg strengths).

·         Inactive Ingredients:

REYATAZ Capsules: crospovidone, lactose monohydrate, and the magnesium stearate. The capsule shells contain gelatin, FD&C Blue No. 2, titanium dioxide, black iron oxide, red iron oxide, and yellow iron oxide. The capsules are printed with ink containing shellac, titanium dioxide, FD&C Blue No. 2, isopropyl alcohol, ammonium hydroxide, propylene glycol, n-butyl alcohol, simethicone, and dehydrated alcohol.


REYATAZ Capsules are available as follows: 150 mg capsule strength, blue cap/powder blue body with BMS 150 mg printed on the cap in white ink and 3624 printed on the body in blue ink, 60 capsules per bottle. 200 mg capsule strength, blue cap/blue body with BMS 200 mg printed on the cap in white ink and 3631 printed on the body in white ink, 60 capsules per bottle.

Bristol-Myers Squibb Company

Princeton, New Jersey 08543 USA

 

Manufactured by:

AstraZeneca Pharmaceuticals LP

4601 Highway 62 East

Mount Vernon, Indiana 47620 USA

 

Secondary Packaged by:

Batterjee Pharma - Jeddah - KSA

 

d. This leaflet was last approved in March 2018

e. To report any side effect(s):


March 2018
  نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)

رياتاز هو دواء يصرف بوصفة طبية لعلاج عدوى فيروس نقص المناعة البشرية- النوع 1 ويستخدم مع الأدوية الأخرى المضادة للفيروسات القهقرية لعلاج عدوى فيروس نقص المناعة البشرية-1 لدى البالغين. فيروس نقص المناعة البشرية هو الفيروس الذي يسبب مرض نقص المناعة المكتسب (إيدز).

يجب ألا يستخدم رياتاز في حالات الأطفال دون سن 3 أشهر.

عند استخدامه مع أدوية أخرى مضادة للفيروسات القهقرية لعلاج عدوى فيروس نقص المناعة البشرية-1، قد يساعد رياتاز على:

  • تقليل نسبة فيروس نقص المناعة البشرية -1 في الدم. وهذا يطلق عليه "الحمل الفيروسي".
  • زيادة عدد خلايا تي المساعدة CD4 في الدم وهذا يساعد على مكافحة العداوى الأخرى.

 

ربما يساعد تقليل نسبة فيروس نقص المناعة البشرية-1 وزيادة عدد خلايا تي المساعدة CD4 في الدم على تحسين جهازك المناعي. وهذا يمكن أن يقلل من احتمالية الوفاة أو الإصابة بعداوى يمكن أن تصيبك عندما يكون جهازك المناعي ضعيفاً (العداوى الانتهازية).

رياتاز لا يعالج عدوى فيروس نقص المناعة البشرية-1 أو الإيدز. يجب عليك الاستمرار في استخدام أدوية عدوى فيروس نقص المناعة البشرية-1 للتحكم في عدوى فيروس نقص المناعة البشرية والحد من الأمراض المتعلقة بفيروس نقص المناعة البشرية.

أ‌.         لا تتناول رياتاز في حالة

·           إذا كان لديك حساسية تجاه آتازنفير أو أي من مكونات رياتاز. انظر نهاية تلك النشرة للقائمة الكاملة للمكونات الموجودة في رياتاز.

·           إذا كنت تتناول أي من الأدوية التالية. يمكن أن يؤثر تناول رياتاز مع هذه الأدوية على أداء رياتاز. ويمكن أن يسبب رياتاز آثاراً جانبية مميتة أو يؤدي إلى الوفاة عند استخدامه مع هذه الأدوية:

·           ألفوزوسين (يوروكساترال®)

·           سيسابريد (بروبولسيد®)

·           غرازوبريفير/إلباسفير (زيباتير ®)

·           أدوية مرض الأرغوت مثل:

·         طرطرات الإرغوتامين (كافيرغوت®، ميغيرغوت ®، إرغومار ®، إرغوستات ®، ميديهايلر ®، إرغوتامين ®، ويغراين ®، ويغريتس ®)

·         ميسيلات ثنائي هيدروأرغوتامين (دي. إتش. إي. 45 ®، ميغرانال ®)

·         ميثيل الإرغونوفين (ميثرجين®)

·           إندينافير (كريكسيفان®)

·           إرينوتيكان (كامبتوزار®)

·           لوراسيدون (لاتودا®) إذا استخدم رياتاز مع ريتونافير (نورفير®)

·           لوفاستاتين (أدفيكور®، ألتوبريف®، ميفاكور®)

·           ميدازولام (فيرسيد®) عندما يؤخذ عن طريق الفم للتهدئة

·           نيفيرابين (فيراميون®، فيراميون إكس آر®)

·           بيموزيد (أوراب®)

·           ريفامبين (ريفادين®، ريفاميت®، ريفاتير®، ريمكتان®)

·           سيلدينافيل (ريفاتيو®) عند استخدامه لعلاج ارتفاع ضغط الدم الرئوي

·           سيمفاستاتين (سيمكور®، فيتورين®، زوكور®)

·           نبتة سانت جون (هايبيريكم بيرفراتم)

·           مافيريت (جليكابريفير/بيبرينتازفير)

·           تريازولام (هالسيون®)

 

يمكن أن تحدث مشاكل خطيرة إذا تناولت أنت أو طفلك أي من الأدوية السابق ذكرها مع رياتاز.

ب‌.     كن حريصاً عند استخدام رياتاز

ما الذي يجب أن أخبر به مسؤول الرعاية الصحية قبل تناول رياتاز؟

قبل تناول رياتاز، أخبر مسؤول الرعاية الصحية بالآتي:

·           إذا كنت تعاني من مشاكل بالقلب

·           إذا كنت تعاني مشاكل بالكبد، بما في ذلك فيروس الالتهاب الكبدي الوبائي بي أو سي.

·           إذا كنت تتلقى علاجاً للغسيل الكلوي

·           إذا كنت تعاني مرض السكري.

·           إذا كنت تعاني مرض الناعور.

·           إذا كنت تعاني من أي حالات طبية أخرى

ج. تناول أدوية أخرى أو أدوية عشبية أو مكملات غذائية

·           أخبر مسؤول الرعاية الصحية بكل الأدوية التي تتناولها، بما في ذلك الأدوية الموصوفة وغير الموصوفة والفيتامينات والمكملات الغذائية العشبية.

بعض الأدوية تتفاعل مع رياتاز. احتفظ بقائمة تتضمن جميع الأدوية التي تتناولها لتطلع مسؤول الرعاية الصحية أو الصيدلي عليها. يمكنك أن تطلب من مسؤول الرعاية الصحية أو الصيدلي قائمة تتضمن الأدوية التي تتفاعل مع رياتاز. لا تبدأ تناول دواء جديد دون إخبار مسؤول الرعاية الصحية. يمكن أن يخبرك مسؤول الرعاية الصحية إذا كان تناول رياتاز مع الأدوية الأخرى آمناً أم لا.

د . استخدام رياتاز مع الطعام والشراب

انظر كيف تستخدم رياتاز (4)

هـ. الحمل والرضاعة

قبل تناول رياتاز، أخبري مسؤول الرعاية الصحية:

·           إذا كنتِ حاملاً أو تخططين للحمل. تحدثي إلى مسؤول الرعاية الصحية حول تناول رياتاز خلال فترة حملك أو إذا كنتِ تخططين للحمل بينما تتناولين رياتاز.

·           ربما يتأثر أداء موانع الحمل الهرمونية مثل الحقن أو الحلقات المهبلية أو الزرع تحت الجلد أو اللاصقة وبعض حبوب منع الحمل خلال فترة العلاج برياتاز. تحدثي إلى مسؤول الرعاية الصحية حول موانع الحمل التي يمكن استخدامها خلال فترة العلاج برياتاز.

·           بعد ولادة الطفل، قومي بإخبار مسؤول الرعاية الصحية الخاص بكِ إذا تحول لون جلد طفلك أو الجزء الأبيض من عينيه للأصفر.

·           إذا كنتِ ترضعين أو تخططين لإرضاع طفلك رضاعة طبيعية. توقفي عن الرضاعة الطبيعية إذا كنتِ تتناولين رياتاز. ينبغي ألا تقومي بإرضاع طفلك رضاعة طبيعية إذا كنتِ مصابة بفيروس نقص المناعة-1 حتى لا ينتقل المرض لطفلك عبر الرضاعة. كما يمكن أن ينتقل رياتاز لطفلك عن طريق لبن الثدي. تحدثي إلى مسؤول الرعاية الصحية حول أفضل طريقة لإرضاع طفلك.

    و. القيادة واستخدام الآلات

يجب أن يكون المريض على علم بأنه قد تم الإبلاغ عن الإصابة بالدوار أثناء العلاج بالأنظمة التي تحتوي على رياتاز.

ز. معلومات مهمة حول بعض مكونات رياتاز

يحتوي رياتاز على اللاكتوز. إذا قام طبيب بإخبارك أن لديك حساسية مفرطة لبعض أنواع السكر (مثل: اللاكتوز)، فتحدث إلى طبيبك قبل استخدام رياتاز.

https://localhost:44358/Dashboard

·           قم باستخدام رياتاز طبقاً لتعليمات مسؤول الرعاية الصحية الخاص بك تماماً.

·           لا تقم بتغيير جرعتك أو التوقف عن تناول رياتاز ما لم يخبرك مسؤول الرعاية الصحية بذلك.

·           يجب أن تظل خاضعاً لرعاية مسؤول الرعاية الصحية خلال فترة العلاج برياتاز.

·           يجب استخدام رياتاز مع الأدوية القهقرية الأخرى.

·           تناول رياتاز مرة واحدة يومياً.

·           رياتاز يأتي في صورة كبسولات.

·           تناول كبسولات رياتاز مع الطعام.

·           ابتلع الكبسولات كاملة. لا تفتح الكبسولات.

·           إذا نسيت جرعة من رياتاز، فقم بأخذها في أقرب وقت ممكن وبعدها قم بأخذ الجرعة التالية في موعدها المحدد. لا تضاعف الجرعة التالية.

·           إذا تناولت أكثر من الجرعة المحددة من رياتاز،قم بالاتصال بمسؤول الرعاية الصحية الخاص بك أو توجه إلى قسم الطوارئ بأقرب مستشفى فوراً.

عندما يبدأ مخزونك من رياتاز في النقصان، قم بالحصول على المزيد من مسؤول الرعاية الصحية الخاص بك أو الصيدلية. من المهم ألا ينفد ما لديك من رياتاز. قد تزداد كمية فيروس نقص المناعة في دمك إذا توقف تناول الدواء حتى لفترة قصيرة. وربما يصبح الفيروس مقاوماً لرياتاز ويصعب علاجه.

 

مثل كل الأدوية، من الممكن أن يتسبب رياتاز في أعراض جانبية مع أنه لا يُصاب بها كل الأشخاص.

من الآثار الجانبية الأكثر شيوعاً لرياتاز:

·         غثيان

·         صداع

·         ألم في منطقة البطن

·         قيء

·         مشاكل في النوم

·         خدر أو وخز أو حرقة اليدين أو القدمين

·         دوار

·         ألم العضلات

·         إسهال

·         اكتئاب

·         حمى

أخبر مسؤول الرعاية الصحية إذا كنت تعاني من آثار جانبية تزعجك أو لا تختفي.

هذه ليست جميع الآثار الجانبية المحتملة لرياتاز. لمزيد من المعلومات، استشر مسؤول الرعاية الصحية أو الصيدلي.

اتصل بطبيبك لطلب المشورة الطبية حول الآثار الجانبية.

 

·           احفظ كبسولات رياتاز في درجة حرارة الغرفة، بين 20 و25 درجة مئوية.

·           احفظ الكبسولات في علبة محكمة الغلق.

 

احفظ رياتاز وجميع الأدوية بعيداً عن متناول الأطفال.

·         مادة فعالة: كبريتات آتازنفير (في جرعات 150 مجم و200 مجم)

·         مواد غير فعالة:

كبسولات رياتاز: كروسبوفيدون، مونوهيدرات اللاكتوز، ستيرات المغنيسيوم. يحتوي غلاف الكبسولات على الجيلاتين، ملون أزرق براق (FD&C) رقم 2، ثاني أكسيد التيتانيوم، أكسيد الحديد الأسود، أكسيد الحديد الأحمر، وأكسيد الحديد الأصفر. الكبسولات مطبوعة بحبر يحتوي على اللك، ثاني أكسيد التيتانيوم، ملون أزرق براق (FD&C) رقم 2، كحول الأيزوبروبيل، هيدروكسيد الأمونيوم، بروبيلين غليكول، كحول البوتيل العادي، سيميثيكون، كحول منزوع الماء.

كبسولات رياتاز متوفرة كالتالي:

كبسولات ذات تركيز 150 مجم، غطاء /مسحوق أزرق جسم أزرق مع BMS 150 mgm مطبوعة على الغطاء بحبر أبيض و3624 مطبوعة على الجسم بحبر أزرق، 60 كبسولة للزجاجة.

كبسولات ذات تركيز 200 مجم، غطاء أزرق/جسم أزرق مع BMS 200 mgm مطبوعة على الغطاء بحبر أبيض و3631 مطبوعة على الجسم بحبر أبيض، 60 كبسولة للزجاجة.

شركة بريستول مايرز سكويب

برينستون، نيو جيرسي 08543 الولايات المتحدة

المصنع:

شركة أسترا زينيكا إل بي

4601 الطريق السريع 62 شرق

ماونت فيرنون، إنديانا 47620 الولايات المتحدة

 

التعبئة الثانوية:

البتريجي للأدوية- جدة- المملكة العربية السعودية

مارس 2018
 Read this leaflet carefully before you start using this product as it contains important information for you

REYATAZ (atazanavir) Capsules 150 mg capsule 200 mg capsule

The active ingredient in REYATAZ capsules is atazanavir sulfate, which is an HIV-1 protease inhibitor. The chemical name for atazanavir sulfate is (3S,8S,9S,12S)-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester, sulfate (1:1). Its molecular formula is C38H52N6O7●H2SO4, which corresponds to a molecular weight of 802.9 (sulfuric acid salt). The free base molecular weight is 704.9. Atazanavir sulfate has the following structural formula: Atazanavir sulfate is a white to pale-yellow crystalline powder. It is slightly soluble in water (4–5 mg/mL, free base equivalent) with the pH of a saturated solution in water being about 1.9 at 24  3C. For a full list of excipients, see section 6.1.

REYATAZ (atazanavir) capsules are available in the following strengths and configurations of plastic bottles with child-resistant closures. * 150 mg atazanavir equivalent to 170.8 mg atazanavir sulfate. 200 mg atazanavir equivalent to 227.8 mg atazanavir sulfate.

REYATAZÒ (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients 18 years and older.

Limitations of Use:

·         REYATAZ is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus.

·         Use of REYATAZ/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Pharmacodynamic properties (5.1)].

REYATAZÒ (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients 18 years and older.

Limitations of Use:

·         REYATAZ is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus.

·         Use of REYATAZ/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Pharmacodynamic properties (5.1)].

 


·         REYATAZ capsules must be taken with food.

·         Do not open the capsules.

·         The recommended oral dosage of REYATAZ depends on the treatment history of the patient and the use of other coadministered drugs. When coadministered with H2‑receptor antagonists or proton-pump inhibitors, dose separation may be required.

·         REYATAZ capsules without ritonavir are not recommended for treatment-experienced adult patients with prior virologic failure [see Pharmacodynamic properties (5.1)].

·         Efficacy and safety of REYATAZ with ritonavir when ritonavir is administered in doses greater than 100 mg once daily have not been established. The use of higher ritonavir doses may alter the safety profile of atazanavir (cardiac effects, hyperbilirubinemia) and, therefore, is not recommended. Prescribers should consult the complete prescribing information for ritonavir when using ritonavir.

·         The correct REYATAZ dosage may be achieved by using a combination of commercially available capsules:

§  REYATAZ 300 mg (use two 150 mg capsules).

§  REYATAZ 400 mg once daily (use two 200 mg capsules).

Testing Prior to Initiation and During Treatment with REYATAZ

Renal laboratory testing should be performed in all patients prior to initiation of REYATAZ and continued during treatment with REYATAZ. Renal laboratory testing should include serum creatinine, estimated creatinine clearance, and urinalysis with microscopic examination [see Special warnings and precautions for use (4.4)].

Hepatic laboratory testing should be performed in patients with underlying liver disease prior to initiation of REYATAZ and continued during treatment with REYATAZ [see Special warnings and precautions for use (4.4)].

Dosage of REYATAZ in Adult Patients

Table 1 displays the recommended dosage of REYATAZ capsules in treatment-naive and treatment-experienced adults. Table 1 also displays recommended dosage of REYATAZ and ritonavir when given concomitantly with other antiretroviral drugs and H2-receptor antagonists (H2RA). Ritonavir is required with several REYATAZ dosing regimens (see the ritonavir complete prescribing information about the safe and effective use of ritonavir). The use of REYATAZ in treatment-experienced adult patients without ritonavir is not recommended.

a See Interaction with other medicinal products and other forms of interaction (4.5) for instructions concerning coadministration of acid reducing medications (eg, H2RA or proton pump inhibitors [PPIs]), and other antiretroviral drugs (eg, efavirenz, tenofovir DF, and didanosine).

Dosage Adjustments in Pregnant Patients

Table 2 includes the recommended dosage of REYATAZ capsules and ritonavir in treatment-naive and treatment-experienced pregnant patients. In these patients, REYATAZ must be administered with ritonavir. There are no dosage adjustments for postpartum patients (see Table 1 for the recommended REYATAZ dosage in adults) [Fertility, Pregnancy and lactation (4.6)].

a   See Interaction with other medicinal products and other forms of interaction (4.5) for instructions concerning coadministration of acid reducing medications (eg, H2RA or PPIs), and other antiretroviral drugs (eg, efavirenz, tenofovir DF, and didanosine).

b   REYATAZ is not recommended for treatment-experienced pregnant patients during the second and third trimester taking REYATAZ with both tenofovir DF and H2RA.

Dosage in Patients with Renal Impairment

For patients with renal impairment, including those with severe renal impairment who are not managed with hemodialysis, no dose adjustment is required for REYATAZ. Treatment-naive patients with end stage renal disease managed with hemodialysis should receive REYATAZ 300 mg with ritonavir 100 mg. REYATAZ is not recommended in to HIV-treatment-experienced patients with end stage renal disease managed with hemodialysis [see Pharmacokinetic properties (5.2)].

Dosage in Patients with Hepatic Impairment

 

Table 3 displays the recommended REYATAZ dosage in treatment-naïve patients with hepatic impairment. The use of REYATAZ in patients with severe hepatic impairment (Child-Pugh Class C) is not recommended. The coadministration of REYATAZ with ritonavir in patients with any degree of hepatic impairment is not recommended.

Pediatric Use

Reyataz capsule is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients 6 years of age and older weighing at least 15 kg. REYATAZ is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see Therapeutic indications (41)]. All REYATAZ contraindications, warnings, and precautions apply to pediatric patients [see Contraindications (4.3) and Special warnings and precautions for use (4.4)].

There are no dosing recommendations for REYATAZ capsules in pediatric patients less than 6 years of age.

The safety, pharmacokinetic profile, and virologic response of REYATAZ in pediatric patients were established in an open-label, multicenter clinical trial PACTG 1020A [see Pharmacodynamic properties (5.1)]. The safety profile in pediatric patients was generally similar to that observed in adults [see Tabulated list of adverse reactions (4.8b)].See Posology and method of administration (4.2) for dosing recommendations for the use of REYATAZ capsules in pediatric patients.

Age/Gender

A study of the pharmacokinetics of atazanavir was performed in young (n=29; 18–40 years) and elderly (n=30; ³65 years) healthy subjects. There were no clinically important pharmacokinetic differences observed due to age or gender.

Geriatric Use

Clinical studies of REYATAZ did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Based on a comparison of mean single-dose pharmacokinetic values for Cmax and AUC, a dose adjustment based upon age is not recommended. In general, appropriate caution should be exercised in the administration and monitoring of REYATAZ in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

 

 

 


REYATAZ is contraindicated: • in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of REYATAZ capsules [see Special warnings and precautions for use (4.4)]. • when coadministered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or life-threatening events (see Table 4) • when coadministered with drugs that strongly induce CYP3A and may lead to lower exposure and loss of efficacy of REYATAZ (see Table 4). Table 4: Drugs that are Contraindicated with REYATAZ (Information in the table applies to REYATAZ with or without ritonavir, unless otherwise indicated)

Cardiac Conduction Abnormalities

REYATAZ has been shown to prolong the PR interval of the electrocardiogram in some patients. In healthy volunteers and in patients, abnormalities in atrioventricular (AV) conduction were asymptomatic and generally limited to first-degree AV block. There have been reports of second-degree AV block and other conduction abnormalities [see Undesirable effects, Tabulated list of adverse reactions (4.8b) and Overdose (4.9)]. In clinical trials that included electrocardiograms, asymptomatic first-degree AV block was observed in 5.9% of atazanavir-treated patients (n=920), 5.2% of lopinavir/ritonavir-treated patients (n=252), 10.4% of nelfinavir-treated patients (n=48), and 3.0% of efavirenz-treated patients (n=329). In Study AI424-045, asymptomatic first-degree AV block was observed in 5% (6/118) of atazanavir/ritonavir-treated patients and 5% (6/116) of lopinavir/ritonavir-treated patients who had on-study electrocardiogram measurements. Because of limited clinical experience in patients with preexisting conduction system disease (eg, marked first-degree AV block or second- or third-degree AV block), ECG monitoring should be considered in these patients [see Pharmacodynamic properties (5.1)].

Severe Skin Reactions

In controlled clinical trials, rash (all grades, regardless of causality) occurred in approximately 20% of patients treated with REYATAZ. The median time to onset of rash in clinical studies was 7.3 weeks and the median duration of rash was 1.4 weeks. Rashes were generally mild-to-moderate maculopapular skin eruptions. Treatment-emergent adverse reactions of moderate or severe rash (occurring at a rate of ³2%) are presented for the individual clinical studies [see Undesirable effects, Tabulated list of adverse reactions (4.8b)]. Dosing with REYATAZ was often continued without interruption in patients who developed rash. The discontinuation rate for rash in clinical trials was <1%. Cases of Stevens-Johnson syndrome, erythema multiforme, and toxic skin eruptions, including drug rash, eosinophilia and systemic symptoms (DRESS) syndrome, have been reported in patients receiving REYATAZ [see Contraindications (4.3) and Undesirable effects (4.8a)]. REYATAZ should be discontinued if severe rash develops.

Hepatotoxicity

Patients with underlying hepatitis B or C viral infections or marked elevations in transaminases before treatment may be at increased risk for developing further transaminase elevations or hepatic decompensation. In these patients, hepatic laboratory testing should be conducted prior to initiating therapy with REYATAZ and during treatment [see Undesirable effects (4.8b) and Posology and method of administration (4.2)].

Chronic Kidney Disease

Chronic kidney disease in HIV-infected patients treated with atazanavir, with or without ritonavir, has been reported during postmarketing surveillance. Reports included biopsy-proven cases of granulomatous interstitial nephritis associated with the deposition of atazanavir drug crystals in the renal parenchyma. Consider alternatives to REYATAZ in patients at high risk for renal disease or with preexisting renal disease. Renal laboratory testing (including serum creatinine, estimated creatinine clearance, and urinalysis with microscopic examination) should be conducted in all patients prior to initiating therapy with REYATAZ and continued during treatment with REYATAZ. Expert consultation is advised for patients who have confirmed renal laboratory abnormalities while taking REYATAZ. In patients with progressive kidney disease discontinuation of REYATAZ may be considered [see Posology and method of administration (4.2) and Undesirable effects (4.8b)].

Nephrolithiasis and Cholelithiasis

Cases of nephrolithiasis and/or cholelithiasis have been reported during postmarketing surveillance in HIV-infected patients receiving REYATAZ therapy. Some patients required hospitalization for additional management and some had complications. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made. If signs or symptoms of nephrolithiasis and/or cholelithiasis occur, temporary interruption or discontinuation of therapy may be considered [see Undesirable effects (4.8b)].

Risk of Serious Adverse Reactions Due to Drug Interaction

Initiation of REYATAZ with ritonavir, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving REYATAZ with ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of REYATAZ with ritonavir, respectively. These interactions may lead to:

·         clinically significant adverse reactions potentially leading to severe, life threatening, or fatal events from greater exposures of concomitant medications.

·         clinically significant adverse reactions from greater exposures of REYATAZ with ritonavir.

·         loss of therapeutic effect of REYATAZ with ritonavir and possible development of resistance.

See Table 16 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations [see Drug Interactions (7)]. Consider the potential for drug interactions prior to and during REYATAZ/ritonavir therapy; review concomitant medications during REYATAZ/ritonavir therapy; and monitor for the adverse reactions associated with the concomitant medications [see Contraindications (4.3) and Interaction with other medicinal products and other forms of interaction (4.5)].

Hyperbilirubinemia

Most patients taking REYATAZ experience asymptomatic elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase (UGT). This hyperbilirubinemia is reversible upon discontinuation of REYATAZ. Hepatic transaminase elevations that occur with hyperbilirubinemia should be evaluated for alternative etiologies. No long-term safety data are available for patients experiencing persistent elevations in total bilirubin >5 times the upper limit of normal (ULN). Alternative antiretroviral therapy to REYATAZ may be considered if jaundice or scleral icterus associated with bilirubin elevations presents cosmetic concerns for patients. Dose reduction of atazanavir is not recommended since long-term efficacy of reduced doses has not been established [see Undesirable effects (4.8a)].

Diabetes Mellitus/Hyperglycemia

New-onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, and hyperglycemia have been reported during postmarketing surveillance in HIV-infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease inhibitor therapy and these events has not been established [see Undesirable effects (4.8b)].

Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including REYATAZ. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jiroveci pneumonia, or tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.

Fat Redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

Hemophilia

There have been reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in patients with hemophilia type A and B treated with protease inhibitors. In some patients additional factor VIII was given. In more than half of the reported cases, treatment with protease inhibitors was continued or reintroduced. A causal relationship between protease inhibitor therapy and these events has not been established.

Resistance/Cross-Resistance

Various degrees of cross-resistance among protease inhibitors have been observed. Resistance to atazanavir may not preclude the subsequent use of other protease inhibitors [see Pharmacokinetic properties (5.1)].

`


See also Contraindications (4.3) and Pharmacokinetic properties (5.2).

Potential for REYATAZ to Affect Other Drugs

Atazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.

Atazanavir is a weak inhibitor of CYP2C8. Use of REYATAZ without ritonavir is not recommended when coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide). When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected [see Pharmacodynamic properties (5.2)].

The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir. See the complete prescribing information for ritonavir for information on drug interactions with ritonavir.

Potential for Other Drugs to Affect REYATAZ

Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.

Atazanavir solubility decreases as pH increases. Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with REYATAZ [see Posology and method of administration (4.2)].

Established and Other Potentially Significant Drug Interactions

Table 5 provides dosing recommendations in adults as a result of drug interactions with REYATAZ. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.

 

Drugs with No Observed Interactions with REYATAZ

No clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, atenolol, or the nucleoside reverse transcriptase inhibitors lamivudine or zidovudine [see Pharmacokinetic properties (5.2)].


Pregnancy Category B

Risk Summary

Atazanavir has been evaluated in a limited number of women during pregnancy. Available human and animal data suggest that atazanavir does not increase the risk of major birth defects overall compared to the background rate [see Data]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. No treatment-related malformations were observed in rats and rabbits, for which the atazanavir exposures were 0.7-1.2 times of those at the human clinical dose (300 mg/day atazanavir boosted with 100 mg/day ritonavir). When atazanavir was administered to rats during pregnancy and throughout lactation, reversible neonatal growth retardation was observed [see Data].

Clinical Considerations

Dose Adjustments during Pregnancy and the Postpartum Period

·         REYATAZ must be administered with ritonavir in pregnant women.

·         For pregnant patients, no dosage adjustment is required for REYATAZ with the following exceptions:

o   For treatment-experienced pregnant women during the second or third trimester, when REYATAZ is coadministered with either an H2-receptor antagonist or tenofovir DF, REYATAZ 400 mg with ritonavir 100 mg once daily is recommended. There are insufficient data to recommend a REYATAZ dose for use with both an H2-receptor antagonist and tenofovir DF in treatment-experienced pregnant women.

·         No dosage adjustment is required for postpartum patients. However, patients should be closely monitored for adverse events because atazanavir exposures could be higher during the first 2 months after delivery [see Fertility, pregnancy and lactation (4.6) and Pharmacokinetic properties (5.2)].

Maternal Adverse Reactions

Cases of lactic acidosis syndrome, sometimes fatal, and symptomatic hyperlactatemia have occurred in pregnant women using REYATAZ in combination with nucleosides analogues, which are associated with an increased risk of lactic acidosis syndrome.

Hyperbilirubinemia occurs frequently in patients who take REYATAZ [see Special warnings and precautions for use (4.4)], including pregnant women [see Data].

Advise pregnant women of the potential risks of lactic acidosis syndrome and hyperbilirubinemia.

Fetal/Neonatal Adverse Reactions

All infants, including neonates exposed to REYATAZ in utero, should be monitored for the development of severe hyperbilirubinemia during the first few days of life [see Data].

Data

Human Data

In clinical trial AI424-182, REYATAZ/ritonavir (300/100 mg or 400/100 mg) in combination with zidovudine/lamivudine was administered to 41 HIV-infected pregnant women during the second or third trimester. Among the 39 women who completed the study, 38 women achieved an HIV RNA less than 50 copies/mL at time of delivery. Six of 20 (30%) women on REYATAZ/ritonavir 300/100 mg and 13 of 21 (62%) women on REYATAZ/ritonavir 400/100 mg experienced hyperbilirubinemia (total bilirubin greater than or equal to 2.6 times ULN). There were no cases of lactic acidosis observed in clinical trial AI424‑182.

Atazanavir drug concentrations in fetal umbilical cord blood were approximately 12–19% of maternal concentrations. Among the 40 infants born to 40 HIV-infected pregnant women, all had test results that were negative for HIV-1 DNA at the time of delivery and/or during the first 6 months postpartum. All 40 infants received antiretroviral prophylactic treatment containing zidovudine. No evidence of severe hyperbilirubinemia (total bilirubin levels greater than 20 mg/dL) or acute or chronic bilirubin encephalopathy was observed among neonates in this study. However, 10/36 (28%) infants (6 greater than or equal to 38 weeks gestation and 4 less than 38 weeks gestation) had bilirubin levels of 4 mg/dL or greater within the first day of life.

Lack of ethnic diversity was a study limitation. In the study population, 33/40 (83%) infants were Black/African American, who have a lower incidence of neonatal hyperbilirubinemia than Caucasians and Asians. In addition, women with Rh incompatibility were excluded, as well as women who had a previous infant who developed hemolytic disease and/or had neonatal pathologic jaundice (requiring phototherapy).

Additionally, of the 38 infants who had glucose samples collected in the first day of life, 3 had adequately collected serum glucose samples with values of less than 40 mg/dL that could not be attributed to maternal glucose intolerance, difficult delivery, or sepsis.

Based on prospective reports from the APR of approximately 1600 live births following exposure to atazanavir-containing regimens (including 1037 live births in infants exposed in the first trimester and 569 exposed in second/third trimesters), there was no difference between atazanavir and overall birth defects compared with the background birth defects in clinically recognized pregnancies in 2-4%.

Animal Data

In animal reproduction studies, there was no evidence of mortality or teratogenicity in offspring born to animals at systemic drug exposure levels (AUC) 0.7 (in rabbits) to 1.2 (in rats) times those observed at the human clinical dose (300 mg/day atazanavir boosted with 100 mg/day ritonavir). In pre- and postnatal development studies in the rat, atazanavir caused neonatal growth retardation during lactation that reversed after weaning. Maternal drug exposure at this dose was 1.3 times the human exposure at the recommended clinical exposure. Minimal maternal toxicity occurred at this exposure level.

Breastfeeding (Nursing Mothers)

Risk Summary

The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1. Atazanavir has been detected in human milk. No data are available regarding atazanavir effects on milk production. Atazanavir was present in the milk of lactating rats and was associated with neonatal growth retardation that reversed after weaning.

Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed.


Patients should be informed that dizziness has been reported during treatment with regimens containing REYATAZ [see Undesirable effects (4.8)].


a.         Summary of the safety profile

The following adverse reactions are discussed in greater detail in other sections of the labeling:

  • cardiac conduction abnormalities [see Special warnings and precautions for use (4.4)]
  • rash [see Special warnings and precautions for use (4.4)]
  • hyperbilirubinemia [see Special warnings and precautions for use (4.4)]
  • chronic kidney disease [see Special warnings and precautions for use (4.4)]
  • nephrolithiasis and cholelithiasis [see Special warnings and precautions for use (4.4)]

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety profile of REYATAZ in treatment-naive adults is based on 1625 HIV-1 infected patients in clinical trials. 536 patients received REYATAZ 300 mg with ritonavir 100 mg and 1089 patients received REYATAZ 400 mg or higher (without ritonavir).

The most common adverse reactions were nausea, jaundice/scleral icterus, and rash.

b.         Tabulated list of adverse reactions

Adverse Reactions in Treatment-Naive Adult Patients

Selected clinical adverse reactions of moderate or severe intensity reported in ³2% of treatment-naive patients receiving combination therapy including REYATAZ 300 mg with ritonavir 100 mg and REYATAZ 400 mg (without ritonavir) are presented in Tables 6 and 7, respectively.

 

Adverse Reactions in Treatment-Experienced Adult Patients

The safety profile of REYATAZ in treatment-experienced adults is based on 119 HIV-1 infected patients in clinical trials.

The most common adverse reactions are jaundice/scleral icterus and myalgia.

Selected clinical adverse reactions of moderate or severe intensity reported in ³2% of treatment-experienced patients receiving REYATAZ/ritonavir are presented in Table 8.

 

Laboratory Abnormalities in Treatment-Naive Patients

The percentages of adult treatment-naive patients treated with combination therapy including REYATAZ
300 mg with ritonavir 100 mg and REYATAZ 400 mg (without ritonavir) with Grade 3–4 laboratory abnormalities are presented in Tables 9 and 10, respectively.

Change in Lipids from Baseline in Treatment-Naive Patients

For Study AI424-138 and Study AI424-034, changes from baseline in LDL-cholesterol, HDL-cholesterol, total cholesterol, and triglycerides are shown in Tables 11 and 12, respectively.

 

Laboratory Abnormalities in Treatment-Experienced Patients

The percentages of adult treatment-experienced patients treated with combination therapy including REYATAZ/ritonavir with Grade 3–4 laboratory abnormalities are presented in Table 13.

Change in Lipids from Baseline in Treatment-Experienced Patients

For Study AI424-045, changes from baseline in LDL-cholesterol, HDL-cholesterol, total cholesterol, and triglycerides are shown in Table 14. The observed magnitude of dyslipidemia was less with REYATAZ/ritonavir than with lopinavir/ritonavir. However, the clinical impact of such findings has not been demonstrated.

Postmarketing Experience

The following events have been identified during postmarketing use of REYATAZ. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body as a Whole: edema

Cardiovascular System: second-degree AV block, third-degree AV block, left bundle branch block, QTc prolongation [see Special warnings and precautions for use (4.4)]

Gastrointestinal System: pancreatitis

Hepatic System: hepatic function abnormalities

Hepatobiliary Disorders: cholelithiasis [see Special warnings and precautions for use (4.4)], cholecystitis, cholestasis

Metabolic System and Nutrition Disorders: diabetes mellitus, hyperglycemia [see Special warnings and precautions for use (4.4)]

Musculoskeletal System: arthralgia

Renal System: nephrolithiasis [see Special warnings and precautions for use (4.4)], interstitial nephritis, granulomatous interstitial nephritis, chronic kidney disease [see Special warnings and precautions for use (4.4)]

Skin and Appendages: alopecia, maculopapular rash [see Contraindications (4.3) and Special warnings and precautions for use (4.4)], pruritus, angioedema

c.          Description of selected adverse reactions

Immune-reactivation syndrome

In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalized and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary. Autoimmune disorders (such as Graves' disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment [see Special warnings and precautions for use (4.4)].

 

Osteonecrosis

Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement. The frequency of this is unknown [see Special warnings and precautions for use (4.4)].

 

Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients, including loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy, and dorsocervical fat accumulation (buffalo hump).

 

Combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia, and hyperlactataemia [see Special warnings and precautions for use (4.4) and Pharmacodynamic properties (5.1)].

 

Rash and associated syndromes

Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 3 weeks of starting therapy with REYATAZ.

 

Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported in patients receiving REYATAZ. Patients should be advised of the signs and symptoms and monitored closely for skin reactions. REYATAZ should be discontinued if severe rash develops [see Special warnings and precautions for use (4.4)].

 

 

d.         Other special populations

Adverse Reactions in Patients Co-Infected with Hepatitis B and/or Hepatitis C Virus

Liver function tests should be monitored in patients with a history of hepatitis B or C.

In Study AI424-138, 60 patients treated with REYATAZ/ritonavir 300 mg/100 mg once daily, and 51 patients treated with lopinavir/ritonavir 400 mg/100 mg twice daily, each with fixed dose tenofovir DF-emtricitabine, were seropositive for hepatitis B and/or C at study entry. ALT levels >5 times ULN developed in 10% (6/60) of the REYATAZ/ritonavir-treated patients and 8% (4/50) of the lopinavir/ritonavir-treated patients. AST levels >5 times ULN developed in 10% (6/60) of the REYATAZ/ritonavir-treated patients and none (0/50) of the lopinavir/ritonavir-treated patients.

In Study AI424-045, 20 patients treated with REYATAZ/ritonavir 300 mg/100 mg once daily, and 18 patients treated with lopinavir/ritonavir 400 mg/100 mg twice daily, were seropositive for hepatitis B and/or C at study entry. ALT levels >5 times ULN developed in 25% (5/20) of the REYATAZ/ritonavir-treated patients and 6% (1/18) of the lopinavir/ritonavir-treated patients. AST levels >5 times ULN developed in 10% (2/20) of the REYATAZ/ritonavir-treated patients and 6% (1/18) of the lopinavir/ritonavir-treated patients.

In Studies AI424-008 and AI424-034, 74 patients treated with 400 mg of REYATAZ once daily, 58 who received efavirenz, and 12 who received nelfinavir were seropositive for hepatitis B and/or C at study entry. ALT levels >5 times ULN developed in 15% of the REYATAZ-treated patients, 14% of the efavirenz-treated patients, and 17% of the nelfinavir-treated patients. AST levels >5 times ULN developed in 9% of the REYATAZ-treated patients, 5% of the efavirenz-treated patients, and 17% of the nelfinavir-treated patients. Within REYATAZ and control regimens, no difference in frequency of bilirubin elevations was noted between seropositive and seronegative patients [see Special warnings and precautions for use (4.4)].

See Posology and method of administration (4.2).

 


Human experience of acute overdose with REYATAZ is limited. Single doses up to 1200 mg (three times the 400 mg maximum recommended dose) have been taken by healthy volunteers without symptomatic untoward effects. A single self-administered overdose of 29.2 g of REYATAZ in an HIV-infected patient (73 times the 400‑mg recommended dose) was associated with asymptomatic bifascicular block and PR interval prolongation. These events resolved spontaneously. At REYATAZ doses resulting in high atazanavir exposures, jaundice due to indirect (unconjugated) hyperbilirubinemia (without associated liver function test changes) or PR interval prolongation may be observed [See Special warnings and precautions for use (4.4) and Pharmacodynamic properties (5.1)].

Treatment of overdosage with REYATAZ should consist of general supportive measures, including monitoring of vital signs and ECG, and observations of the patient’s clinical status. If indicated, elimination of unabsorbed atazanavir should be achieved by emesis or gastric lavage. Administration of activated charcoal may also be used to aid removal of unabsorbed drug. There is no specific antidote for overdose with REYATAZ. Since atazanavir is extensively metabolized by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicine.

 


Pharmacotherapeutic group: protease inhibitor

ATC code: J05AE08

Mechanism of Action

Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions.

Pharmacodynamic effects

Cardiac Electrophysiology

Concentration- and dose-dependent prolongation of the PR interval in the electrocardiogram has been observed in healthy volunteers receiving atazanavir. In a placebo-controlled study (AI424‑076), the mean (±SD) maximum change in PR interval from the predose value was 24 (±15) msec following oral dosing with 400 mg of atazanavir (n=65) compared to 13 (±11) msec following dosing with placebo (n=67). The PR interval prolongations in this study were asymptomatic. There is limited information on the potential for a pharmacodynamic interaction in humans between atazanavir and other drugs that prolong the PR interval of the electrocardiogram [see Special warnings and precautions for use (4.4)].

Electrocardiographic effects of atazanavir were determined in a clinical pharmacology study of 72 healthy subjects. Oral doses of 400 mg (maximum recommended dosage) and 800 mg (twice the maximum recommended dosage) were compared with placebo; there was no concentration-dependent effect of atazanavir on the QTc interval (using Fridericia’s correction). In 1793 HIV-infected patients receiving antiretroviral regimens, QTc prolongation was comparable in the atazanavir and comparator regimens. No atazanavir-treated healthy subject or HIV-infected patient in clinical trials had a QTc interval >500 msec [see Special warnings and precautions for use (4.4)].

Antiviral Activity in Cell Culture

Atazanavir exhibits anti‑HIV-1 activity with a mean 50% effective concentration (EC50) in the absence of human serum of 2 to 5 nM against a variety of laboratory and clinical HIV-1 isolates grown in peripheral blood mononuclear cells, macrophages, CEM-SS cells, and MT‑2 cells. ATV has activity against HIV-1 Group M subtype viruses A, B, C, D, AE, AG, F, G, and J isolates in cell culture. ATV has variable activity against HIV-2 isolates (1.9 - 32 nM), with EC50 values above the EC50 values of failure isolates. Two-drug combination antiviral activity studies with ATV showed no antagonism in cell culture with PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir), NNRTIs (delavirdine, efacirenz, and nevirapine), NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir DF, zalcitabine, and zidovudine), the HIV-1 fusion inhibitor enfuvirtide, and two compounds used in the treatment of viral hepatitis, adefovir and ribavirin, without enhanced cytotoxicity.

Resistance

In Cell Culture: HIV-1 isolates with a decreased susceptibility to ATV have been selected in cell culture and obtained from patients treated with ATV or atazanavir/ritonavir (ATV/RTV). HIV-1 isolates with 93- to 183-fold reduced susceptibility to ATV from three different viral strains were selected in cell culture by 5 months. The substitutions in these HIV-1 viruses that contributed to ATV resistance include I50L, N88S, I84V, A71V, and M46I. Changes were also observed at the protease cleavage sites following drug selection. Recombinant viruses containing the I50L substitution without other major PI substitutions were growth impaired and displayed increased susceptibility in cell culture to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir). The I50L and I50V substitutions yielded selective resistance to ATV and amprenavir, respectively, and did not appear to be cross-resistant.

Clinical Studies of Treatment-Naive Patients: Comparison of Ritonavir-Boosted REYATAZ vs. Unboosted REYATAZ: Study AI424-089 compared REYATAZ 300 mg once daily with ritonavir 100 mg vs. REYATAZ 400 mg once daily when administered with lamivudine and extended-release stavudine in HIV-infected treatment-naive patients. A summary of the number of virologic failures and virologic failure isolates with ATV resistance in each arm is shown in Table 15.

Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 300 mg with Ritonavir 100 mg: In Phase III Study AI424-138, an as-treated genotypic and phenotypic analysis was conducted on samples from patients who experienced virologic failure (HIV-1 RNA ³400 copies/mL) or discontinued before achieving suppression on ATV/RTV (n=39; 9%) and LPV/RTV (n=39; 9%) through 96 weeks of treatment. In the ATV/RTV arm, one of the virologic failure isolates had a 56-fold decrease in ATV susceptibility emerge on therapy with the development of PI resistance-associated substitutions L10F, V32I, K43T, M46I, A71I, G73S, I85I/V, and L90M. The NRTI resistance-associated substitution M184V also emerged on treatment in this isolate conferring emtricitabine resistance. Two ATV/RTV-virologic failure isolates had baseline phenotypic ATV resistance and IAS-defined major PI resistance-associated substitutions at baseline. The I50L substitution emerged on study in one of these failure isolates and was associated with a 17-fold decrease in ATV susceptibility from baseline and the other failure isolate with baseline ATV resistance and PI substitutions (M46M/I and I84I/V) had additional IAS-defined major PI substitutions (V32I, M46I, and I84V) emerge on ATV treatment associated with a 3-fold decrease in ATV susceptibility from baseline. Five of the treatment failure isolates in the ATV/RTV arm developed phenotypic emtricitabine resistance with the emergence of either the M184I (n=1) or the M184V (n=4) substitution on therapy and none developed phenotypic tenofovir disoproxil resistance. In the LPV/RTV arm, one of the virologic failure patient isolates had a 69-fold decrease in LPV susceptibility emerge on therapy with the development of PI substitutions L10V, V11I, I54V, G73S, and V82A in addition to baseline PI substitutions L10L/I, V32I, I54I/V, A71I, G73G/S, V82V/A, L89V, and L90M. Six LPV/RTV virologic failure isolates developed the M184V substitution and phenotypic emtricitabine resistance and two developed phenotypic tenofovir disoproxil resistance.

Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 400 mg without Ritonavir: ATV-resistant clinical isolates from treatment-naive patients who experienced virologic failure on REYATAZ 400 mg treatment without ritonavir often developed an I50L substitution (after an average of 50 weeks of ATV therapy), often in combination with an A71V substitution, but also developed one or more other PI substitutions (eg, V32I, L33F, G73S, V82A, I85V, or N88S) with or without the I50L substitution. In treatment-naive patients, viral isolates that developed the I50L substitution, without other major PI substitutions, showed phenotypic resistance to ATV but retained in cell culture susceptibility to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir); however, there are no clinical data available to demonstrate the effect of the I50L substitution on the efficacy of subsequently administered PIs.

Clinical Studies of Treatment-Experienced Patients: In studies of treatment-experienced patients treated with ATV or ATV/RTV, most ATV-resistant isolates from patients who experienced virologic failure developed substitutions that were associated with resistance to multiple PIs and displayed decreased susceptibility to multiple PIs. The most common protease substitutions to develop in the viral isolates of patients who failed treatment with ATV 300 mg once daily and RTV 100 mg once daily (together with tenofovir DFand an NRTI) included V32I, L33F/V/I, E35D/G, M46I/L, I50L, F53L/V, I54V, A71V/T/I, G73S/T/C, V82A/T/L, I85V, and L89V/Q/M/T. Other substitutions that developed on ATV/RTV treatment including E34K/A/Q, G48V, I84V, N88S/D/T, and L90M occurred in less than 10% of patient isolates. Generally, if multiple PI resistance substitutions were present in the HIV-1 virus of the patient at baseline, ATV resistance developed through substitutions associated with resistance to other PIs and could include the development of the I50L substitution. The I50L substitution has been detected in treatment-experienced patients experiencing virologic failure after long-term treatment. Protease cleavage site changes also emerged on ATV treatment but their presence did not correlate with the level of ATV resistance.

Cross-Resistance

Cross-resistance among PIs has been observed. Baseline phenotypic and genotypic analyses of clinical isolates from ATV clinical trials of PI-experienced patients showed that isolates cross-resistant to multiple PIs were cross-resistant to ATV. Greater than 90% of the isolates with substitutions that included I84V or G48V were resistant to ATV. Greater than 60% of isolates containing L90M, G73S/T/C, A71V/T, I54V, M46I/L, or a change at V82 were resistant to ATV, and 38% of isolates containing a D30N substitution in addition to other changes were resistant to ATV. Isolates resistant to ATV were also cross-resistant to other PIs with >90% of the isolates resistant to indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir, and 80% resistant to amprenavir. In treatment-experienced patients, PI-resistant viral isolates that developed the I50L substitution in addition to other PI resistance-associated substitution were also cross-resistant to other PIs.

Baseline Genotype/Phenotype and Virologic Outcome Analyses

Genotypic and/or phenotypic analysis of baseline virus may aid in determining ATV susceptibility before initiation of ATV/RTV therapy. An association between virologic response at 48 weeks and the number and type of primary PI resistance-associated substitutions detected in baseline HIV-1 isolates from antiretroviral-experienced patients receiving ATV/RTV once daily or lopinavir (LPV)/RTV twice daily in Study AI424-045 is shown in Table 16.

Overall, both the number and type of baseline PI substitutions affected response rates in treatment-experienced patients. In the ATV/RTV group, patients had lower response rates when 3 or more baseline PI substitutions, including a substitution at position 36, 71, 77, 82, or 90, were present compared to patients with 1–2 PI substitutions, including one of these substitutions.

The response rates of antiretroviral-experienced patients in Study AI424-045 were analyzed by baseline phenotype (shift in susceptibility in cell culture relative to reference, Table 17). The analyses are based on a select patient population with 62% of patients receiving an NNRTI-based regimen before study entry compared to 35% receiving a PI-based regimen. Additional data are needed to determine clinically relevant break points for REYATAZ.

Clinical efficacy and safety

Adult Patients without Prior Antiretroviral Therapy

Study AI424-138: a 96-week study comparing the antiviral efficacy and safety of REYATAZ/ritonavir with lopinavir/ritonavir, each in combination with fixed-dose tenofovir DF-emtricitabine in HIV-1-infected treatment-naive subjects. Study AI424-138 was a 96-week, open-label, randomized, multicenter study, comparing REYATAZ (300 mg once daily) with ritonavir (100 mg once daily) to lopinavir with ritonavir (400/100 mg twice daily), each in combination with fixed-dose tenofovir DF with emtricitabine (300/200 mg once daily), in 878 antiretroviral treatment-naive treated patients. Patients had a mean age of 36 years (range: 19–72), 49% were Caucasian, 18% Black, 9% Asian, 23% Hispanic/Mestizo/mixed race, and 68% were male. The median baseline plasma CD4+ cell count was 204 cells/mm3 (range: 2 to 810 cells/mm3) and the mean baseline plasma HIV-1 RNA level was 4.94 log10 copies/mL (range: 2.60 to 5.88 log10 copies/mL). Treatment response and outcomes through Week 96 are presented in Table 18.

Through 96 weeks of therapy, the proportion of responders among patients with high viral loads (ie, baseline HIV RNA ³100,000 copies/mL) was comparable for the REYATAZ/ritonavir (165 of 223 patients, 74%) and lopinavir/ritonavir (148 of 222 patients, 67%) arms. At 96 weeks, the median increase from baseline in CD4+ cell count was 261 cells/mm3 for the REYATAZ/ritonavir arm and 273 cells/mm3 for the lopinavir/ritonavir arm.

Study AI424-034: REYATAZ once daily compared to efavirenz once daily, each in combination with fixed-dose lamivudine + zidovudine twice daily. Study AI424-034 was a randomized, double-blind, multicenter trial comparing REYATAZ (400 mg once daily) to efavirenz (600 mg once daily), each in combination with a fixed-dose combination of lamivudine (3TC) (150 mg) and zidovudine (ZDV) (300 mg) given twice daily, in 810 antiretroviral treatment-naive patients. Patients had a mean age of 34 years (range: 18 to 73), 36% were Hispanic, 33% were Caucasian, and 65% were male. The mean baseline CD4+ cell count was 321 cells/mm3 (range: 64 to 1424 cells/mm3) and the mean baseline plasma HIV-1 RNA level was 4.8 log10 copies/mL (range: 2.2 to 5.9 log10 copies/mL). Treatment response and outcomes through Week 48 are presented in Table 19.

Through 48 weeks of therapy, the proportion of responders among patients with high viral loads (ie, baseline HIV RNA ³100,000 copies/mL) was comparable for the REYATAZ and efavirenz arms. The mean increase from baseline in CD4+ cell count was 176 cells/mm3 for the REYATAZ arm and 160 cells/mm3 for the efavirenz arm.

Study AI424-008: REYATAZ 400 mg once daily compared to REYATAZ 600 mg once daily, and compared to nelfinavir 1250 mg twice daily, each in combination with stavudine and lamivudine twice daily. Study AI424-008 was a 48-week, randomized, multicenter trial, blinded to dose of REYATAZ, comparing REYATAZ at two dose levels (400 mg and 600 mg once daily) to nelfinavir (1250 mg twice daily), each in combination with stavudine (40 mg) and lamivudine (150 mg) given twice daily, in 467 antiretroviral treatment-naive patients. Patients had a mean age of 35 years (range: 18 to 69), 55% were Caucasian, and 63% were male. The mean baseline CD4+ cell count was 295 cells/mm3 (range: 4 to 1003 cells/mm3) and the mean baseline plasma HIV-1 RNA level was 4.7 log10 copies/mL (range: 1.8 to 5.9 log10 copies/mL). Treatment response and outcomes through Week 48 are presented in Table 20.

Through 48 weeks of therapy, the mean increase from baseline in CD4+ cell count was 234 cells/mm3 for the REYATAZ 400-mg arm and 211 cells/mm3 for the nelfinavir arm.

Adult Patients with Prior Antiretroviral Therapy

Study AI424-045: REYATAZ once daily + ritonavir once daily compared to REYATAZ once daily + saquinavir (soft gelatin capsules) once daily, and compared to lopinavir + ritonavir twice daily, each in combination with tenofovir DF + one NRTI. Study AI424-045 was a randomized, multicenter trial comparing REYATAZ (300 mg once daily) with ritonavir (100 mg once daily) to REYATAZ (400 mg once daily) with saquinavir soft gelatin capsules (1200 mg once daily), and to lopinavir + ritonavir (400/100 mg twice daily), each in combination with tenofovir DF and one NRTI, in 347 (of 358 randomized) patients who experienced virologic failure on HAART regimens containing PIs, NNRTIs, and NRTIs. The mean time of prior exposure to antiretrovirals was 139 weeks for PIs, 85 weeks for NNRTIs, and 283 weeks for NRTIs. The mean age was 41 years (range: 24 to 74); 60% were Caucasian, and 78% were male. The mean baseline CD4+ cell count was 338 cells/mm3 (range: 14 to 1543 cells/mm3) and the mean baseline plasma HIV-1 RNA level was 4.4 log10 copies/mL (range: 2.6 to 5.88 log10 copies/mL).

Treatment outcomes through Week 48 for the REYATAZ/ritonavir and lopinavir/ritonavir treatment arms are presented in Table 21. REYATAZ/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV RNA level. Study AI424-045 was not large enough to reach a definitive conclusion that REYATAZ/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV RNA lower limit of quantification [see Pharmacokinetic properties (5.2), Tables 16 and 17].

 

No patients in the REYATAZ/ritonavir treatment arm and three patients in the lopinavir/ritonavir treatment arm experienced a new-onset CDC Category C event during the study.

In Study AI424-045, the mean change from baseline in plasma HIV-1 RNA for REYATAZ 400 mg with saquinavir (n=115) was −1.55 log10 copies/mL, and the time-averaged difference in change in HIV-1 RNA levels versus lopinavir/ritonavir was 0.33. The corresponding mean increase in CD4+ cell count was 72 cells/mm3. Through 48 weeks of treatment, the proportion of patients in this treatment arm with plasma HIV-1 RNA <400 (<50) copies/mL was 38% (26%). In this study, coadministration of REYATAZ and saquinavir did not provide adequate efficacy [see Interaction with other medicinal products and other forms of interaction (4.5)].

Study AI424-045 also compared changes from baseline in lipid values [see Undesirable effects (4.8a)].

Study AI424-043: Study AI424-043 was a randomized, open-label, multicenter trial comparing REYATAZ (400 mg once daily) to lopinavir/ritonavir (400/100 mg twice daily), each in combination with two NRTIs, in 300 patients who experienced virologic failure to only one prior PI-containing regimen. Through 48 weeks, the proportion of patients with plasma HIV-1 RNA <400 (<50) copies/mL was 49% (35%) for patients randomized to REYATAZ (n=144) and 69% (53%) for patients randomized to lopinavir/ritonavir (n=146). The mean change from baseline was −1.59 log10 copies/mL in the REYATAZ treatment arm and −2.02 log10 copies/mL in the lopinavir/ritonavir arm. Based on the results of this study, REYATAZ without ritonavir is inferior to lopinavir/ritonavir in PI-experienced patients with prior virologic failure and is not recommended for such patients.

 


Pharmacokinetics
The pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV-infected patients
after administration of REYATAZ 400 mg once daily and after administration of REYATAZ 300 mg with
ritonavir 100 mg once daily (see Table 22).

Absorption

Atazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours. Atazanavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC and Cmax values over the dose range of 200 to 800 mg once daily. Steady state is achieved between Days 4 and 8, with an accumulation of approximately 2.3 fold.

Food Effect

Administration of REYATAZ with food enhances bioavailability and reduces pharmacokinetic variability. Administration of a single 400-mg dose of REYATAZ with a light meal (357 kcal, 8.2 g fat, 10.6 g protein) resulted in a 70% increase in AUC and 57% increase in Cmax relative to the fasting state. Administration of a single 400-mg dose of REYATAZ with a high-fat meal (721 kcal, 37.3 g fat, 29.4 g protein) resulted in a mean increase in AUC of 35% with no change in Cmax relative to the fasting state. Administration of REYATAZ  with either a light meal or high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately one-half compared to the fasting state.

Coadministration of a single 300-mg dose of REYATAZ and a 100-mg dose of ritonavir with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 33% increase in the AUC and a 40% increase in both the Cmax and the 24-hour concentration of atazanavir relative to the fasting state. Coadministration with a high-fat meal (951 kcal, 54.7 g fat, 35.9 g protein) did not affect the AUC of atazanavir relative to fasting conditions and the Cmax was within 11% of fasting values. The 24-hour concentration following a high-fat meal was increased by approximately 33% due to delayed absorption; the median Tmax increased from 2.0 to 5.0 hours. Coadministration of REYATAZ with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately 25% compared to the fasting state.

Distribution

Atazanavir is 86% bound to human serum proteins and protein binding is independent of concentration. Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively). In a multiple-dose study in HIV-infected patients dosed with REYATAZ 400 mg once daily with a light meal for 12 weeks, atazanavir was detected in the cerebrospinal fluid and semen. The cerebrospinal fluid/plasma ratio for atazanavir (n=4) ranged between 0.0021 and 0.0226 and seminal fluid/plasma ratio (n=5) ranged between 0.11 and 4.42.

Metabolism

Atazanavir is extensively metabolized in humans. The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation. Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N‑dealkylation, hydrolysis, and oxygenation with dehydrogenation. Two minor metabolites of atazanavir in plasma have been characterized. Neither metabolite demonstrated in vitro antiviral activity. In vitro studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A.

Elimination

Following a single 400-mg dose of 14C‑atazanavir, 79% and 13% of the total radioactivity was recovered in the feces and urine, respectively. Unchanged drug accounted for approximately 20% and 7% of the administered dose in the feces and urine, respectively. The mean elimination half-life of atazanavir in healthy volunteers (n=214) and HIV-infected adult patients (n=13) was approximately 7 hours at steady state following a dose of 400 mg daily with a light meal.

Specific Populations

Renal Impairment

In healthy subjects, the renal elimination of unchanged atazanavir was approximately 7% of the administered dose. REYATAZ has been studied in adult subjects with severe renal impairment (n=20), including those on hemodialysis, at multiple doses of 400 mg once daily. The mean atazanavir Cmax was 9% lower, AUC was 19% higher, and Cmin was 96% higher in subjects with severe renal impairment not undergoing hemodialysis (n=10), than in age-, weight-, and gender-matched subjects with normal renal function. In a 4-hour dialysis session, 2.1% of the administered dose was removed. When atazanavir was administered either prior to, or following hemodialysis (n=10), the geometric means for Cmax, AUC, and Cmin were approximately 25% to 43% lower compared to subjects with normal renal function. The mechanism of this decrease is unknown. REYATAZ is not recommended for use in HIV-treatment-experienced patients with end-stage renal disease managed with hemodialysis [see Posology and method of administration (4.2)].

Hepatic Impairment

REYATAZ has been studied in adult subjects with moderate-to-severe hepatic impairment (14 Child-Pugh B and 2 Child-Pugh C subjects) after a single 400-mg dose. The mean AUC(0-¥) was 42% greater in subjects with impaired hepatic function than in healthy volunteers. The mean half-life of atazanavir in hepatically impaired subjects was 12.1 hours compared to 6.4 hours in healthy volunteers. A dose reduction to 300 mg is recommended for patients with moderate hepatic impairment (Child-Pugh Class B) who have not experienced prior virologic failure as increased concentrations of atazanavir are expected. REYATAZ is not recommended for use in patients with severe hepatic impairment. The pharmacokinetics of REYATAZ in combination with ritonavir has not been studied in subjects with hepatic impairment, thus, coadministration of REYATAZ with ritonavir is not recommended for use in patients with any degree of hepatic impairment [see Posology and method of administration (4.2)].

Pregnancy

The pharmacokinetic data from HIV-infected pregnant women receiving REYATAZ Capsules with ritonavir are presented in Table 23.

Drug Interaction Data

Atazanavir is a metabolism-dependent CYP3A inhibitor, with a Kinact value of 0.05 to 0.06 min-1 and Ki value of 0.84 to 1.0 µM. Atazanavir is also a direct inhibitor for UGT1A1 (Ki=1.9 µM) and CYP2C8 (Ki=2.1 µM).

Atazanavir has been shown in vivo not to induce its own metabolism, nor to increase the biotransformation of some drugs metabolized by CYP3A. In a multiple-dose study, REYATAZ decreased the urinary ratio of endogenous 6b-OH cortisol to cortisol versus baseline, indicating that CYP3A production was not induced.

Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, DYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8. See the complete prescribing information for ritonavir for information on other potential drug interactions with ritonavir.

Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ and dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).

Drug interaction studies were performed with REYATAZ and other drugs likely to be coadministered and some drugs commonly used as probes for pharmacokinetic interactions. The effects of coadministration of REYATAZ on the AUC, Cmax, and Cmin are summarized in Tables 24 and 25. Neither didanosine EC nor diltiazem had a significant effect on atazanavir exposures (see Table 24 for effect of atazanavir on didanosine EC or diltiazem exposures). REYATAZ did not have a significant effect on the exposures of didanosine (when administered as the buffered tablet), stavudine, or fluconazole. For information regarding clinical recommendations, see Interaction with other medicinal products and other forms of interaction (4.5).

 

Data provided are under fed conditions unless otherwise noted.

b  All drugs were given under fasted conditions.

c  REYATAZ 300 mg plus ritonavir 100 mg once daily coadministered with famotidine 40 mg twice daily resulted in atazanavir geometric mean Cmax that was similar and AUC and Cmin values that were 1.79- and 4.46-fold higher relative to REYATAZ 400 mg once daily alone.

d  Similar results were noted when famotidine 20 mg BID was administered 2 hours after and 10 hours before atazanavir 300 mg and ritonavir 100 mg plus tenofovir DF 300 mg.

e  Atazanavir/ritonavir/tenofovir DF was administered after a light meal.

f   Study was conducted in HIV-infected individuals.

g    Compared with atazanavir 400 mg historical data without nevirapine (n=13), the ratio of geometric means (90% confidence intervals) for Cmax, AUC, and Cmin were 1.42 (0.98, 2.05), 1.64 (1.11, 2.42), and 1.25 (0.66, 2.36), respectively, for atazanavir/ritonavir 300/100 mg; and 2.02 (1.42, 2.87), 2.28 (1.54, 3.38), and 1.80 (0.94, 3.45), respectively, for atazanavir/ritonavir 400/100 mg.

h  Parallel group design; n=23 for atazanavir/ritonavir plus nevirapine, n=22 for atazanavir 300 mg/ritonavir 100 mg without nevirapine. Subjects were treated with nevirapine prior to study entry.

i   Omeprazole 40 mg was administered on an empty stomach 2 hours before REYATAZ.

j     Omeprazole 20 mg was administered 30 minutes prior to a light meal in the morning and REYATAZ 300 mg plus ritonavir 100 mg in the evening after a light meal, separated by 12 hours from omeprazole.

k  REYATAZ 300 mg plus ritonavir 100 mg once daily separated by 12 hours from omeprazole 20 mg daily resulted in increases in atazanavir geometric mean AUC (10%) and Cmin (2.4-fold), with a decrease in Cmax (29%) relative to REYATAZ 400 mg once daily in the absence of omeprazole (study days 1–6).

l   Omeprazole 20 mg was given 30 minutes prior to a light meal in the morning and REYATAZ 400 mg plus ritonavir 100 mg once daily after a light meal, 1 hour after omeprazole. Effects on atazanavir concentrations were similar when REYATAZ 400 mg plus ritonavir 100 mg was separated from omeprazole 20 mg by 12 hours.

m REYATAZ 400 mg plus ritonavir 100 mg once daily administered with omeprazole 20 mg once daily resulted in increases in atazanavir geometric mean AUC (32%) and Cmin (3.3-fold), with a decrease in Cmax (26%) relative to REYATAZ 400 mg once daily in the absence of omeprazole (study days 1–6).

n  Compared with atazanavir 400 mg QD historical data, administration of atazanavir/ritonavir 300/100 mg QD increased the atazanavir geometric mean values of Cmax, AUC, and Cmin by 18%, 103%, and 671%, respectively.

o  Note that similar results were observed in studies where administration of tenofovir DF and REYATAZ was separated by 12 hours.

p  Ratio of atazanavir plus ritonavir plus tenofovir DF to atazanavir plus ritonavir. Atazanavir 300 mg plus ritonavir 100 mg results in higher atazanavir exposure than atazanavir 400 mg (see footnote o). The geometric mean values of atazanavir pharmacokinetic parameters when coadministered with ritonavir and tenofovir DF were: Cmax = 3190 ng/mL, AUC = 34459 ng·h/mL, and Cmin = 491 ng/mL. Study was conducted in HIV-infected individuals.

NA = not available.

 


Carcinogenesis

Long-term carcinogenicity studies in mice and rats were carried out with atazanavir for two years. In the mouse study, drug-related increases in hepatocellular adenomas were found in females at 360 mg/kg/day. The systemic drug exposure (AUC) at the NOAEL (no observable adverse effect level) in females, (120 mg/kg/day) was 2.8 times and in males (80 mg/kg/day) was 2.9 times higher than those in humans at the clinical dose (300 mg/day atazanavir boosted with 100 mg/day ritonavir, non-pregnant patients). In the rat study, no drug-related increases in tumor incidence were observed at doses up to 1200 mg/kg/day, for which AUCs were 1.1 (males) or 3.9 (females) times those measured in humans at the clinical dose.

Mutagenesis

Atazanavir tested positive in an in vitro clastogenicity test using primary human lymphocytes, in the absence and presence of metabolic activation. Atazanavir tested negative in the in vitro Ames reverse-mutation assay, in vivo micronucleus and DNA repair tests in rats, and in vivo DNA damage test in rat duodenum (comet assay).

Impairment of Fertility

At the systemic drug exposure levels (AUC) 0.9 (in male rats) or 2.3 (in female rats) times that of the human clinical dose, (300 mg/day atazanavir boosted with 100 mg/day ritonavir) significant effects on mating, fertility, or early embryonic development were not observed.


Aspartame (E951)
Sucrose


Not applicable.


2 years

Do not store REYATAZ (atazanavir) Capsules above 30°C.


REYATAZÒ (atazanavir) Capsules are available in the following strengths and configurations of plastic bottles with child-resistant closures.

 


No special requirements.

Patient Counseling Information

REYATAZ is not a cure for HIV infection. Advise patients to remain under the care of a healthcare provider while using REYATAZ.

Cardiac Conduction Abnormalities

Inform patients that atazanavir may produce changes in the electrocardiogram (eg, PR prolongation). Tell patients to consult their healthcare provider if they are experiencing symptoms such as dizziness or lightheadedness [see Special warnings and precautions for use (4.4)].

Severe Skin Reaction

Inform patients that there have been reports of severe skin reactions (eg, Stevens-Johnson syndrome, erythema multiforme, and toxic skin eruptions) with REYATAZ use. Advise patients that if signs or symptoms of severe skin reactions or hypersensitivity reactions develop, they must discontinue REYATAZ and seek medical evaluation immediately [see Special warnings and precautions for use (4.4) and Undesirable effects (4.8a)].

Hyperbilirubinemia

Inform patients that asymptomatic elevations in indirect bilirubin have occurred in patients receiving REYATAZ. This may be accompanied by yellowing of the skin or whites of the eyes and alternative antiretroviral therapy may be considered if the patient has cosmetic concerns [see Special warnings and precautions for use (4.4)].

Chronic Kidney Disease

Inform patients that treatment with REYATAZ may lead to the development of chronic kidney disease, and to maintain adequate hydration while taking REYATAZ [see Special warnings and precautions for use (4.4)].

Nephrolithiasis and Cholelithiasis

Inform patients that kidney stones and/or gallstones have been reported with REYATAZ use. Some patients with kidney stones and/or gallstones required hospitalization for additional management and some had complications. Discontinuation of REYATAZ may be necessary as part of the medical management of these adverse events [see Special warnings and precautions for use (4.4)].

Drug Interactions

REYATAZ may lead to significant interaction with some drugs; therefore, advise patients to report the use of any other prescription, nonprescription medication, or herbal products, particularly St. John’s wort, to their healthcare provider prior to use [see Contraindications (4.3), and Special warnings and precautions for use (4.4)].

Fat Redistribution

Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy including protease inhibitors and that the cause and long-term health effects of these conditions are not known at this time [see Special warnings and precautions for use (4.4)].

Dosing Instructions

Advise patients to take REYATAZ with food every day and take other concomitant antiretroviral therapy as prescribed. REYATAZ must always be used in combination with other antiretroviral drugs. Advise patients that they should not alter the dose or discontinue therapy without consulting with their healthcare provider. Tell patients if a dose of REYATAZ is missed, they should take the dose as soon as possible and then return to their normal schedule; however, if a dose is skipped the patient shouldn’t not double the next dose.


Bristol-Myers Squibb Company Princeton, New Jersey 08543 USA Manufactured by: AstraZeneca Pharmaceuticals LP 4601 Highway 62 East Mount Vernon, Indiana 47620 USA Secondary Packaged by: Batterjee Pharma - Jeddah - KSA

Mar 2018
}

صورة المنتج على الرف

الصورة الاساسية